Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
OKYO Pharma enrolled the first patients in its Phase 3 NEPTUNE pivotal trial of urcosimod for neuropathic corneal pain. The study targets a chronic eye-pain condition with no FDA-approved therapies.
OKYO Pharma has enrolled the first patients in its Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain. This registrational study includes sites in the U.S. and Europe.
OKYO Pharma Limited has announced the enrollment of the first patients in a Phase 3 pivotal trial for its investigational therapy, Urcosimod, aimed at treating neuropathic corneal pain.